Ideas
Buy Samsung on healthy pullback.
Samsung Electronics' two-day surge of more than 15% makes a 2-3% pullback a healthy buying opportunity, not a sell signal. The speaker expects any gap fill toward the 129,000-130,000 won area to be a buy zone, and says investors should not sell because Q4 guidance on January 8 and potential quarterly operating profit near 20 trillion won could lead to 30-35 trillion won quarterly profit and Citi's 155 trillion won annual estimate; valuation remains undemanding at about 2.2x PBR. He prefers Samsung over SK hynix on a pullback.
Hold SK hynix; prefer Samsung on dips.
Semiconductor holdings should be kept, including SK hynix. On a relative basis, the speaker prefers Samsung Electronics over SK hynix if both pull back because Samsung may correct more and offer the better entry.
Hold Hanmi; new high expected.
Hold Hanmi Semiconductor. The speaker expects the stock to break to a new all-time high because bonding equipment is becoming increasingly important, the company's recent value-enhancement announcement was received well, and an analyst report is expected soon.
Hold Korean semiconductor equipment stocks.
Major Korean semiconductor equipment and materials stocks should be held. The sector is rallying even without capacity expansion, and the speaker says it is still right to own leading equipment names.
Nuclear regulatory easing drives opportunity.
Nuclear power is becoming a favorable theme as regulations are eased, U.S. states such as New York and Ontario support nuclear, data-center developers are seeking nuclear power, and the Genesis Mission's core is nuclear; faster permitting could pull projects forward by years.
Buy Doosan Enerbility on nuclear, gas turbines.
Buy Doosan Enerbility without overthinking. Foreign investors bought about 280 billion won and roughly 2 million shares, nuclear regulatory easing is a powerful catalyst, and its gas-turbine capability is a differentiating asset as data centers scramble for power; if it gaps down, buy into the close, and the speaker does not expect it to break 80,000 won.
Hold ABL Bio on foreign buying.
ABL Bio was the strongest bio stock in the prior session and foreign investors bought it most among KOSDAQ names, but the speaker will not recommend new buying; holders should hold into the JPM Healthcare Conference catalysts.
Buy Alteogen after 20% correction.
Alteogen is the one bio name the speaker would buy. It has corrected about 20% from its high, which he calls a sale, and the option contract language is meaningful. Foreign investors are buying ahead of the JPM Healthcare Conference, making the risk-reward attractive.
Watch Korean biotech into JPM Healthcare.
Foreign investors are buying a concentrated set of Korean biotech names ahead of the JPM Healthcare Conference, making ABL Bio, Alteogen, D&D Pharmatech, Olix, and LigaChem Bio important to watch; the conference acts as a marketplace for even small biotech companies to present their technology.
Buy Hyundai Motor as cheap robot stock.
Hyundai Motor is the only major robot stock that has not re-rated. It controls Boston Dynamics and has the robot and autonomous-driving moat within the group, yet trades around 6x P/E and below 1x PBR. The monthly chart has only just started to break out, so the speaker says to buy now and again on pullbacks, with 400,000 won as a potential level.
Avoid Kia; Hyundai holds robot moat.
Kia is relatively weak in the robot theme because Hyundai Motor holds the Boston Dynamics and robot moat; the robot value re-rating is accruing to Hyundai, not Kia, so the speaker flags Kia as unattractive on a relative basis.
Buy Hyundai AutoEver for robot software.
Hyundai AutoEver is the core autonomous-driving and robotics software play within the Hyundai Motor Group, and the speaker says he has repeatedly recommended it as the key beneficiary of that theme.
Buy power equipment stocks on dip.
The recent sharp drop in HD Hyundai Electric, Hyosung Heavy Industries, and LS Electric is a buying opportunity, not a trend reversal. Power demand and semiconductor demand will recover, the stocks should not break their box-range lows, and investors should buy into the close rather than chasing at the open.
Buy defense sector on weapons demand.
Defense stocks are an opportunity. The U.S. action in Venezuela signals a more imperial and hegemonic posture, which should increase weapons demand globally; U.S. defense and drone-related stocks already rose, and Rheinmetall also gained.
Hold D&D Pharmatech for MASH catalyst.
Hold D&D Pharmatech. Its MASH treatment DD01, now partnered with Pfizer after Pfizer acquired Mesera, could be a bigger JPM Healthcare topic than obesity drugs. The 48-week trial has completed, 24-week data is coming, and an acquisition or 48-week results in late February or early March could trigger value; the speaker sees the market cap rising from about 4 trillion won to at least 5 trillion won.
Buy EcoPro on nickel smelter expansion.
EcoPro is attractive because it is acquiring nickel smelters in Indonesia; nickel is not just for batteries but also for high-strength alloys used in SpaceX rocket bodies, and the chairman's New Year address stressed overcoming challenges through R&D, boosting confidence.
This 815 Money Talk (815머니톡) video, published January 06, 2026,
features Lee Kwon-hee
discussing 005930.KS, 000660.KS, 042700.KS, Korean semiconductor equipment/materials sector, URA, 034020.KS, 298380.KQ, 196170.KQ, ABL Bio, Olix, 141080.KQ, 005380.KS, 000270.KS, 307950.KS, 267260.KS, 298040.KS, 010120.KS, ITA, 347850.KQ, 086520.KQ.
16 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Kwon-hee
· Tickers:
005930.KS,
000660.KS,
042700.KS,
Korean semiconductor equipment/materials sector,
URA,
034020.KS,
298380.KQ,
196170.KQ,
ABL Bio,
Olix,
141080.KQ,
005380.KS,
000270.KS,
307950.KS,
267260.KS,
298040.KS,
010120.KS,
ITA,
347850.KQ,
086520.KQ
